Ozempic nation: America's GLP-1 use nearly quadruples in just two yea…

GLP-1 drug use in the United States has nearly quadrupled over two years, signalling massive demand expansion in weight-loss and diabetes treatment markets. This reflects a structural shift in pharmaceutical consumption patterns with implications for supply chains, payer models, and competitive positioning in metabolic health. If you sell anything into the diabetes or weight-loss supply chain—manufacturing, logistics, packing, patient management software, or payer analytics—your addressable market just quadrupled in two years and will keep growing. The constraint now is supply and distribution, not demand; that's where the margin moves.